MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults
Status:
COMPLETED
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
This study is a randomized controlled trial designed to investigate the synergistic effects of combining mindfulness-based cognitive therapy (MBCT) with escitalopram hydrobromide versus escitalopram alone on cognitive function, depressive symptoms, and quality of life in older adults diagnosed with treatment-resistant depression (TRD) and cognitive impairment.